FDA’s economist in chief
Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.
Biotech IPOs; don’t let the numbers deceive
Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — its second-best year ever. Yet, many of the biotech companies that went public in the last quarter of the year were miserable after-market performers.